Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. (ALNY) was submitted on October 28, 2021, reporting events occurring on October 26 and 28, 2021. The filing primarily addresses a significant leadership transition and references the announcement of financial results for the quarter ended September 30, 2021.
Key Financial Metrics
The filing references the announcement of financial results for the quarter ended September 30, 2021, but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity within the text of this report. These details are contained in the attached press release (Exhibit 99.1) and are not summarized in the body of this 8-K.
Material Changes and Leadership Transition
- CEO Appointment: Yvonne L. Greenstreet, MBChB, MBA, currently President and Chief Operating Officer, was appointed Chief Executive Officer, effective January 1, 2022.
- CEO Departure: John M. Maraganore, Ph.D., will depart as CEO and Board member effective December 31, 2021, following nearly 19 years of service. He will join the Scientific Advisory Board.
- Board Composition: The Board expanded from 11 to 12 members on October 28, 2021, with Dr. Greenstreet elected as a Class I director. The Board size will reduce back to 11 members upon Dr. Maraganore's departure.
Compensatory Arrangements and Agreements
A Letter Agreement dated October 26, 2021, outlines the terms of Dr. Maraganore's transition:
- Consulting Role: Dr. Maraganore will provide consulting services for up to 10 hours per month for a three-month period.
- Compensation: He will receive cash compensation equal to his current base rate for three months and a 2021 performance-based cash bonus.
- Equity Treatment: Outstanding unvested equity awards will continue to vest until the second anniversary of the end of the consulting period. Vested stock options remain exercisable until the earlier of the second anniversary of the consulting period end or their original expiration dates.
- Termination Status: The departure is treated as a resignation for "Good Reason" or termination without "Cause."
Investor Verification Checklist
- Review Exhibit 99.1 for specific Q3 2021 financial results (revenue, net loss, cash position) not detailed in this summary.
- Verify the exact vesting schedule and expiration dates for Dr. Maraganore's equity awards in the full Letter Agreement (Exhibit 10.1).
- Confirm the timeline for Dr. Greenstreet's full assumption of CEO duties and the interim management structure between October 2021 and January 2022.
- Monitor future filings for the appointment of a new independent director to replace Dr. Maraganore on the Board.